ER Stress Thwarts Protective Anti-Tumor Immunity Through T-bet Repression
Research results reveal a new role of Chop as an intrinsic mediator of T cell dysfunction in tumors and suggest the therapeutic potential of inhibiting Chop or the UPR mediator Perk in CD8+ T cells as a platform to overcome tumor-induced T cell suppression and a strategy to boost the efficacy of T cell-based immunotherapies. Read more
News
- Bacteriotherapy Heals Cisplatin Damage
- ER Stress Thwarts Protective Anti-Tumor Immunity Through T-bet Repression
- Fighting Cancer with Mathematics and Viruses
- ITUS Enters CAR-T Research Alliance with Moffitt Cancer Center
- Moffitt Researchers Characterize Mechanism of Action of CAR T Cells
- Moffitt Researchers Identify Novel Target to Improve Chemotherapeutic Response in Breast Cancer
- NHLBI selects Moffitt Cancer Center as one of the Cell Therapies Processing Facilities
- S100A9-Induced Overexpression of Pd-1/Pd-L1 Contributes to Ineffective Hematopoiesis In MDS